People with diabetes on semaglutide, in Wegovy and Ozempic, four times more likely to be diagnosed with naion eye disorder
People who have been prescribed a weight-loss injection could be at a higher risk of developing an eye condition which can lead to blindness, a study has found.
The study found that people with diabetes who were prescribed semaglutide, most commonly known under the brand names Wegovy and Ozempic, were over four times more likely to be diagnosed with an eye condition known as non-arteritic anterior ischemic optic neuropathy (naion).
About Author
More Stories
Amazon takes on Musk’s Starlink with launch of first internet satellites
Revealed: Chinese researchers can access half a million UK GP records
Europe must boost space investment to secure autonomy from US, says ESA boss